Candel Therapeutics, Inc.

NasdaqGM:CADL Aktierapport

Börsvärde: US$723.2m

Candel Therapeutics Förvaltning

Förvaltning kriterier kontrolleras 2/4

Candel Therapeutics VD är Paul-Peter Tak, utsedd i Sep 2020, har en mandatperiod på 5.83 år. totala årliga ersättningen är $ 4.95M, bestående av 15% lön 85% bonusar, inklusive företagsaktier och optioner. äger direkt 0.37% av företagets aktier, värda $ 2.65M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4.3 år respektive 6.8 år.

Viktig information

Paul-Peter Tak

Verkställande direktör

US$4.9m

Total ersättning

VD-lön i procent15.03%
Anställning som VD5.8yrs
Ägande av VD0.4%
Ledningens genomsnittliga anställningstid4.3yrs
Styrelsens genomsnittliga mandatperiod6.8yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jul 04

Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential

Summary Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets. I see near-term catalysts in the prostate BLA submission, Phase III AURORA NSCLC trial, and maturing glioma data, with execution risk now outweighing clinical risk. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Candel Therapeutics: Entering Its Pivotal Year

Summary Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. Big risks remain due to its negative EPS and debt ratios, but that potential FDA approval and its varied proprietary platforms make Candel an attractive acquisition target. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Summary Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. Viral therapies like CAN-2409 face commercialization challenges, but the strong phase 3 data justifies maintaining a "Buy" rating for CADL stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 01

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Summary Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells. Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers. CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer. Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion. The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024. Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409. Read the full article on Seeking Alpha
Seeking Alpha • Sep 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the treatment of glioma, which is a type of tumor that occurs in the brain and spinal cord. The European Medicines Agency's (EMA) Committee for Orphan Medical Products issued the positive opinion, CADL said in a statement. CAN-2409 is a genetically modified adenovirus that is currently being evaluated in multiple phase 2 and 3 trials for lung, brain, pancreatic and prostate cancers, CADL said. The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases. CADL said the orphan drug designation follows a U.S. FDA fast track designation granted in June last year for CAN-2409 to be used in combination with antiviral drug valacyclovir to treat newly diagnosed glioma. CADL stock +3.7% to $3.64 in early trading.
Seeking Alpha • Sep 07

Candel Therapeutics appoints CFO, chief medical officer

Biopharmaceutical company Candel Therapeutics (NASDAQ:CADL) appointed Jason Amello CFO and Garrett Nichols chief medical officer. Amello, whose appointment is effective Sep. 21, is replacing John Canepa. Canepa has decided to pursue other interests and spend more time with his family. Amello joins from the rare disease biotech company Saniona, while Nichols joins from Istari Oncology. Source: Press Release
Seeking Alpha • Oct 21

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer. CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer. With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel. Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.

Analys av ersättningar till VD

Hur har Paul-Peter Tak:s ersättning förändrats jämfört med Candel Therapeutics:s resultat?
DatumTotal ersättningLönFöretagets resultat
Mar 31 2026n/an/a

-US$54m

Dec 31 2025US$5mUS$744k

-US$38m

Sep 30 2025n/an/a

-US$23m

Jun 30 2025n/an/a

-US$22m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$1mUS$689k

-US$55m

Sep 30 2024n/an/a

-US$52m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$1mUS$670k

-US$38m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$2mUS$670k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$957kUS$545k

-US$36m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$135k

-US$18m

Ersättning vs marknad: Paul-Peter s total kompensation ($USD 4.95M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 3.56M ).

Ersättning vs inkomst: Ersättningen för Paul-Peter har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Paul-Peter Tak (66 yo)

5.8yrs
Anställning
US$4,947,909
Kompensation

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Paul-Peter Tak
President5.8yrsUS$4.95m0.37%
$ 2.7m
Charles Schoch
Senior VP2.5yrsUS$1.24m0.059%
$ 428.3k
Francesca Barone
Chief Scientific Officer4.4yrsUS$1.36m0.11%
$ 763.5k
Seshu Tyagarajan
Chief Technical & Development Officer4.3yrsUS$613.23k0.11%
$ 827.7k
Ileen Winick
Chief People Officerno datainga uppgifteringa uppgifter
Susan Stewart
Chief Regulatory Officer5.8yrsinga uppgifteringa uppgifter
William Garrett
Chief Medical Officer3.8yrsinga uppgifter0.072%
$ 518.1k
Mark Sims
Chief Commercial Officerno datainga uppgifteringa uppgifter
4.3yrs
Genomsnittlig anställningstid
57.5yo
Genomsnittlig ålder

Erfaren ledning: CADL s ledningsgrupp anses vara erfaren ( 4.3 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Paul-Peter Tak
President5.8yrsUS$4.95m0.37%
$ 2.7m
Edward Benz
Member of Research Advisory Board & Independent Director8.8yrsUS$103.55k0%
$ 0
Paul Manning
Independent Chairman7.7yrsUS$130.55k6.07%
$ 43.9m
Scott Eggener
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Adam Kibel
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
E. Chiocca
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Renee Gaeta
Independent Director3.9yrsUS$103.05k0%
$ 0
Christopher Martell
Independent Director7.7yrsUS$114.55k1.01%
$ 7.3m
Charu Aggarwal
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Steven Albelda
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Mark Bloomston
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Nicoletta Loggia
Independent Director3.1yrsUS$107.02k0.0029%
$ 21.1k
6.8yrs
Genomsnittlig anställningstid
62yo
Genomsnittlig ålder

Erfaren styrelse: CADL s styrelse anses vara erfaren ( 6.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/07/31 02:51
Aktiekurs vid dagens slut2026/07/31 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Candel Therapeutics, Inc. bevakas av 11 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets